Alume Biosciences Announces Publication of Data Examining First-in-Human Use of Bevonescein to Illuminate Nerves in Nature Communications
'These data support our belief that bevonescein can help make surgery more precise by allowing surgeons to see nerves more clearly."
Bevonescein is a novel fluorescent visualization drug designed to selectively illuminate nerves during surgery, helping to prevent inadvertent nerve injury and is currently being evaluated in ongoing Phase 3 clinical trials.
'Currently, many head and neck surgeries result in nerve injuries, which can be catastrophic for the patients,' said Eben L. Rosenthal, MD, Barry Baker Professor and Chair of the Department of Otolaryngology–Head and Neck Surgery at Vanderbilt University Medical Center and study senior author. 'This first-in-human data demonstrate the safety of bevonescein and its potential to enhance nerve visualization in real time. It's especially promising to see improvements in nerve conspicuity at the optimal dose.'
Key Findings:
Fluorescence Superiority: Bevonescein provided enhanced nerve visualization with higher nerve conspicuity scores in fluorescent compared to white light. All participants demonstrated improved visible nerve length; 57% showed more than 20% improvement.
Optimal Dose Defined: The optimal treatment dose of bevonescein was 500mg.
Favorable Safety Profile: No dose-limiting toxicities or infusion reactions occurred. No surgeries were delayed or canceled due to the study drug.
'These data support our belief that bevonescein can help make surgery more precise by allowing surgeons to see nerves more clearly,' said Quyen Nguyen, MD, PhD, Founder and CEO of Alume Biosciences. 'When Roger Tsien and I started work on bevonescein, our vision was to translate his Nobel Prize-winning discoveries regarding fluorescence into tools that directly improve surgical outcomes. This milestone brings us closer to that goal.'
'With the growing adoption of fluorescence guidance in surgery, it's exciting to see this technology now applied to nerve identification,' said Ryan Orosco, MD, Associate Professor, University of New Mexico and the study's co-lead author. 'Bevonescein represents a paradigm shift in how we identify nerves during surgery, and ultimately how we improve patient outcomes.'
Study Overview
The dose-defining and dose-timing clinical trial enrolled 27 adults undergoing elective head and neck surgery including parotidectomy, thyroidectomy and cervical neck dissections. Participants received intravenous bevonescein at varying doses to assess safety, pharmacokinetics, and optimal visualization timing. Surgical visualization of bevonescein-enabled nerve fluorescence was performed using the Zeiss Tivato surgical microscope with Yellow 560. Surgeons assessed nerve visualization using 4-point Likert scale that measured conspicuity, visible nerve length, and delineation of branching.
About Bevonescein (ALM-488)
Bevonescein is Alume's lead compound—a targeted fluorescent peptide-dye conjugate that binds to nerve tissue, enabling intraoperative nerve visualization. It is currently in Phase 3 clinical trials and is planned for New Drug Application (NDA) submission to the U.S. Food and Drug Administration in 2026.
About Alume Biosciences
Alume Biosciences is a biotechnology company pioneering nerve-targeted drugs to enhance surgical precision and preserve nerve function. Founded on a lead candidate co-invented by late Nobel Laureate Dr. Roger Tsien, Alume is committed to translating cutting-edge science into practical tools for surgeons and better outcomes for patients. Learn more at alumebiosciences.com and LinkedIn.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
USA Today
an hour ago
- USA Today
A predictable day of 'horrific injuries': Doctors dread the Fourth of July
Data shows several Americans died from fireworks injuries and more than thousands were injured last year. The Fourth of July is anything but celebratory in the Emergency Room. Every year, doctors amputate fingers and hands damaged by fireworks. They try to save eyes. And sometimes they have to deliver the worst news imaginable to loved ones. That's the warning – and the cold hard truth – from doctors who are bracing for another busy Independence Day. Dr. Nicolas Lee had already amputated the hands of two boys who lost them to firework injuries the week before Fourth of July. He expects to see many more in the coming week. "These are effectively bombs people are holding in their hands," said Lee, a professor of clinical orthopedic surgery at the University of California San Francisco who directs a hand reconstruction program. "We see hands and fingers blown off, groin injuries, facial burns and damage. I've had kids blow off their eyelids so they can't close their eyes." Even though fireworks are legal in much of the nation and sold widely, they are dangerous and deserve care and respect, said Dr. Jeffrey Goodloe. He's already seen burns, lacerations and hand injuries from people holding fireworks. "They're like military battle wounds," said Goodloe, an emergency room physician in Tulsa, Oklahoma who's also vice president for communication for the American College of Emergency Physicians. "These are horrific injuries. People just don't realize that even publicly available fireworks pack enough punch to rip a finger or a hand off." Last year, 11 Americans died from fireworks injuries and more than 14,700 were treated in emergency rooms, according to the U.S. Consumer Product Safety Commission. In more than one-third of cases, the injuries were burns to the hands and fingers or head, face and ears. It's not just big rockets that hurt people. Last year, there were an estimated 1,700 emergency room injuries that only involved sparklers. One wrong move can change a person's life – and those people tend to be young. Almost a quarter of injuries are among people between 15- and 24-years-old and most are men. "I don't remember ever having a woman, it's always been young men," said Lee. 'We're going to see a lot of people who completely changed their lives because they made one simple, bad decision and now either they've lost a hand, they've lost their eyes, they've lost another appendage, or worse,' said Dr. Arvin Akhavan, an emergency medicine physician at the University of Washington. What are the most common firework injuries? The most common injury these doctors see is to the hands. "I've seen a number of people where the firework went off in their hand while they were holding it. Either they didn't have time to set it down or they were thinking they were going to aim it. But it blew up," said Goodloe. The hand literally blows apart, said Lee. The joints, bones, ligaments and skin are disrupted or destroyed by the blast. The most common digit to lose is the thumb. "That's 40% of your hand function," he said. "If it's really bad, the hand looks like a starfish. The fingers, the thumb, all the joints are dislocated and it just splays out," Lee said. "We try to save as many fingers as we can, we try to at least give you something to pinch with," he said. "But sometimes it requires amputation." There are also often facial burns, lacerations and injuries as people peer at fireworks. It's not uncommon for people to lose an eye. "I would love to show you actual photos of what happens, but it's too gruesome," said Chelsea Boe, a hand and microvascular surgeon at the University of Washington in Seattle. There are also groin injuries, if people are either sitting while they're lighting the device, or if they drop it and the blast radiates up towards them. Some injuries are to the solid organs in the core or to the head. "There are people who try to launch them off the top of their head or their chest," Lee said. For people setting off fireworks near shorelines or beaches, Lee has also seen injuries from sand that's cast up by the strength of the explosion. "The sand becomes thousands of little projectiles. It can get embedded in your skin, in your eyes, in your face. It's like getting a tattoo," he said. "It's hard to get out – you can't make that many micro incisions. So often you just have to leave it in." Fireworks safety tips The doctors who spend thousands of hours trying to save fingers, hands, eyes and other damage wish – fervently – that people would take a moment to think before they touch fireworks. "It's gunpowder with a fuse. They go off with unbelievable force and it goes right through the tissues," said Boe. "A lot of time, it's unsupervised kids. Or it's young men and boys who get together with their friends," she said. "They may or may not be drinking or using other substances. They may not be making the best decisions." Here's a few important tips: The damage Lee sees in the operating room is awful – and unnecessary. "It's so devastating and these injuries are entirely preventable," he said. "I hope this (article) can help at least one person from suffering this way." Can fingers be re-attached? In the movies, a person might light a firecracker and blow off a finger cleanly. They stick it in a bucket of ice, race off to the hospital, and it all gets sewn back together. Reality is not so forgiving. "In very few cases, even with a very skilled hand surgeon, are you going to be able to reimplant a finger," said Goodloe. The injuries are rarely clean and neat and the amount of damage to the digit is considerable. "The reality is that when your finger gets blown off, you've permanently lost your finger," he said. When do firework injuries occur? While many injuries occur on the actual Fourth of July, the two weeks before the holiday and the two weeks after are very busy in emergency rooms, as people start to play with fireworks they've purchased or want to set off fireworks they had leftover from the holiday. "For hand surgeons, this is our holiday in the worst possible way," said Boe. It's even worse when the Fourth of July happens near a weekend, as it does this year, because people are more likely to make a weekend of it – and to party and drink. At the University of Washington, which is the main trauma unit for the Seattle region, they saw close to 50 people who required firework injury-related surgery in the four days after the Fourth. "We do a huge amount of preparation. We have extra teams available, extra operating rooms. We cancel elective surgeries, we try to have extra anesthesia teams available," she said. "It's almost like we're triaging for a mass casualty event."
Business Wire
an hour ago
- Business Wire
Tinnitus Research: Novel Compound AC102 Makes Constant Ear Noise Disappear in Preclinical Model
ERLANGEN, Germany & BERLIN--(BUSINESS WIRE)--The novel compound AC102 almost completely reversed tinnitus in a preclinical model after a single dose. At the same time, the damaged connections between the auditory nerve and inner ear sensory cells were restored. These findings were recently published in the prestigious International Journal of Molecular Sciences in a joint study conducted by Erlangen University Hospital and Berlin-based drug developer AudioCure. As there is currently no causal treatment for tinnitus, there is a high medical need. AC102 regenerates connections between the inner ear and auditory nerve in a preclinical model and eliminates tinnitus. Efficacy of AC102 on sudden hearing loss and tinnitus currently investigated in clinical trial. Share In the current study, AC102 was administered to the middle ear of one experimental group after acoustic trauma, while a second group received a placebo. Although both groups initially showed signs of tinnitus, they nearly disappeared in the AC102 group after five weeks – in clear contrast to the placebo group. Additionally, the AC102 group showed significantly less loss of synaptic connections between the inner ear and the auditory nerve than the placebo group. This damage is considered to be a potential cause of tinnitus: 'Our results suggest regeneration of inner ear structures that are critical for tinnitus and could be an important milestone and a glimmer of hope for a causal treatment of tinnitus,' says the study's first author, Dr. Konstantin Tziridis from Erlangen University Hospital. About two-thirds of sudden hearing loss patients also suffer from tinnitus, which persists in around 30% of cases. Although 10-15% of adults experience tinnitus, no effective causal treatment exists. AC102 has the potential to become a new treatment option. In a preclinical acoustic trauma model, it almost completely reversed sudden hearing loss. Since tinnitus often accompanies sudden hearing loss, AudioCure is investigating AC102's potential efficacy also against tinnitus in its ongoing study. AudioCure's CEO, Dr. Reimar Schlingensiepen, emphasizes: "Constant ear noise caused by tinnitus can be even more stressful for many patients than the hearing loss itself. With AC102, we hope to eventually have an effective remedy for both conditions. This would be a great relief for patients and doctors who have no approved drug treatment available at present." AC102 has already been tested for safety and tolerability in a clinical study and is currently being examined in a Europe-wide Phase-2-study in patients for its effectiveness in sudden hearing loss and tinnitus.
Business Wire
5 hours ago
- Business Wire
Medimaps Group Launches In Europe TBS Osteo Next-Generation Software For Advanced Bone Microarchitecture Assessment
GENEVA--(BUSINESS WIRE)--Medimaps Group S.A., a global leader in AI-driven bone microarchitecture imaging solutions, announces the European launch of its MDR-cleared next-generation TBS Osteo Advanced software. Following the product launch in the United States last month, this next milestone reflects the company's commitment to advancing osteoporosis detection and bone health management worldwide. TBS Osteo next-generation is available through a convenient subscription model, a flexible option providing customers with eligibility for software updates, new features and support services. Share The TBS Osteo Advanced software delivers refined correction for soft tissue thickness anterior to the lumbar spine, ensuring inclusivity of TBS assessment across a wide range of body phenotypes. It also introduces new system management capabilities, allowing hospitals and healthcare networks to centrally manage the TBS software on their DXA systems fleet, and to standardize workflows across multiple locations. These improvements enhance operational efficiency, streamline clinical processes, and ensure consistent patient care. TBS Osteo is available through a convenient subscription model, a flexible option providing customers with eligibility for software updates, new features and support services. This approach ensures healthcare organizations stay up to date with the latest innovations in osteoporosis care. Current TBS Osteo users have the possibility to upgrade to the next generation version and to take advantage of the new capabilities. 'The TBS Osteo next-generation software has been developed with busy radiology professionals in mind for a maximum of clinical output with a minimum of logistics. The software is seamlessly integrated into the clinical workflow and performed at time of DXA scan. This approach sets TBS Osteo apart from competition,' said Univ. Prof. Dr. Didier Hans, CEO and Co-founder of Medimaps Group. 'TBS Osteo delivers within seconds a comprehensive report combining BMD and clinical factors, providing results beyond the standard of care. Adopted by many top hospitals across the world, including in the U.S., DXA and TBS Osteo have become the gold standard to detect and monitor osteoporosis.' Since its initial launch in 2012, TBS Osteo has been widely adopted across the world, to support the assessment and management of osteoporosis. The software is backed by over 1,400 peer-reviewed publications and endorsed by more than 30 national and international osteoporosis assessment and management guidelines. In Europe, the software has received clearance from the Medical Device Regulation (MDR) and remains the only approved medical software for bone microarchitecture evaluation in clinical practice. Osteoporosis is a condition that weakens bones and increases the risk of fractures. Fractures due to osteoporosis have a devastating impact on millions of people worldwide and result in enormous socio-economic costs to society and healthcare systems. According to the International Osteoporosis Foundation, approximately 32 million Europeans aged 50 or over have osteoporosis. The annual number of osteoporotic fractures across the European Union, Switzerland, and the United Kingdom is projected to rise from 4.33 million in 2019 to 5.34 million by 2034 - an increase of over 1 million fractures annually¹. Despite the availability of effective treatments to reduce fracture risk, only 1 in 5 patients who experience an osteoporotic fracture are diagnosed or receive appropriate therapy¹. References International Osteoporosis Foundation (IOF), Last accessed: June 24, 2025 About Medimaps Group Founded by medical practitioners and clinical researchers, Medimaps combines Swiss innovation with a global presence to lead in bone health management. We provide healthcare professionals worldwide with advanced AI-driven software that enables comprehensive bone microarchitecture assessment. Our passion for musculoskeletal health is underpinned by scientific knowledge, collaborations with world-class academics, clinicians, industry partners, and direct patient engagement. The science behind our cutting-edge imaging applications and clinical evidence forms the core of our company's DNA. Medimaps Group, headquartered in Geneva, Switzerland, has offices in the United States and France. Its U.S. affiliate, Medimaps Group USA LLC, markets the company products and services. Learn more at
